Sun Pharmaceuticals' Halol plant gets 'import alert' from USFDA

The USFDA had imposed an import ban on the Halol plant in December 2015 too

The Halol facility of Sun Pharmaceuticals, the eighth-largest pharma company in the US generics market, was slapped with an import alert by the US Food and Drug Administration (USFDA), which could result in shipments from the Gujarat plant being refused entry into the USA.

As a result, analysts expect a 2-3 per cent hit to the firm’s top line and a 5-6 percent impact on its earnings before interest, taxes, depreciation, and amortisation (Ebitda).

On Thursday, the company’s stock took a beating, declining 3.57 per cent on the BSE. The USFDA had imposed an import ban on the Halol plant